Saturday 17 October 2026
Export RVPH’s income statement to Excel — free account
Reviva Pharmaceuticals Holdings, Inc.
RVPH Healthcare Biotechnology
In the quarter to June 2026, EPS grew 92.1% and free cash flow grew 57.8%, each against the same quarter a year earlier.
0.45
0.03
−6.25%
Follow RVPH
Reviva Pharmaceuticals Holdings, Inc. (RVPH) P/E ratio
Reviva Pharmaceuticals Holdings, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 147× (May 2019) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 147×
Ten-year median
0.0×
Current reading's percentile
87
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| DRMA Dermata Therapeutics, Inc. compare | n/m |
| LGVN Longeveron Inc. compare | n/m |
| RVPH Reviva Pharmaceuticals Holdings, Inc. | n/m |
| PULM Pulmatrix, Inc. compare | n/m |
| CDIO Cardio Diagnostics Holdings, Inc. compare | n/m |
| CELZ Creative Medical Technology Holdings, Inc. compare | n/m |
| BGMS Bio Green Med Solution, Inc. compare | n/m |
| XBIO Xenetic Biosciences, Inc. compare | n/m |
| PCSA Heatwurx Inc. compare | 1.6× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)